Sepul Bio, Doses First Participant in Phase 2b Clinical Trial of ultevursen for USH2A-associated retinitispigmentosa.

Sepul Bio, an innovative business unit of Laboratoires Théa (“Théa”)dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the first clinical participant has been dosed in LUNA clinical study, a Phase 2b clinical study for ultevursen, in individuals with retinitis pigmentosa (RP) or non-syndromic RP due to variants in exon 13 of the Usher Syndrome Type 2a gene.